Venture
Paragon Biosciences Emalex Capital, Inc.
Latest Form D 2025-07-08- CIK 1749990
- State IL
- Pharmaceuticals
- 5 Form D offerings since 2018-08-14
- Total sold
- $377M
- across 5 offerings
- Rounds
- 5
- Form D offerings since 2018-08-14
- Latest round
- $270M
- 2022-11-04 · 021-463914
- Investors
- 42
- on the latest round
Connected
named in its Form D filingsOfferings · since 2018-08-145 Form D offeringsExemptions506(b)People · Item 3Patrick J. Morris + 6 moreSales · Item 12Paragon Health Capital, LLCInvestors · dashboardInferred investors
Paragon Biosciences Emalex Capital, Inc.CIK 1749990
Round timeline
amount sold · by first filed2022-11-04 · $270M
- 2018-08-14$9.4M021-319146
- 2019-10-03$37.4M021-350344
- 2021-03-12$35M021-392044
- 2022-11-04$25M021-463904
- 2022-11-04$270M021-463914
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($270M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-463914 | First filed2022-11-04 | Latest2025-07-08 | Sought$270M | Sold$270M | Investors42 | Exemptions506(b) |
| 021-463904 | First filed2022-11-04 | Latest2022-11-04 | Sought$25M | Sold$25M | Investors35 | Exemptions506(b) |
| 021-392044 | First filed2021-03-12 | Latest2021-03-12 | Sought$35M | Sold$35M | Investors21 | Exemptions506(b) |
| 021-350344 | First filed2019-10-03 | Latest2019-10-03 | Sought$37.4M | Sold$37.4M | Investors10 | Exemptions506(b) |
| 021-319146 | First filed2018-08-14 | Latest2018-12-07 | Sought$9.4M | Sold$9.4M | Investors31 | Exemptions506(b) |
Who backs Paragon Biosciences Emalex Capital, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2025-07-08
| Name | Relationship |
|---|---|
| Patrick J. Morris | RelationshipExecutive Officer |
| Jeffrey Aronin | RelationshipDirector |
| Antonio Gracias | RelationshipDirector |
| Darien Parhad | RelationshipExecutive Officer |
| Eric Messner | RelationshipExecutive Officer, Director |
| Jeffrey Dayno | RelationshipDirector |
| Ricky Sun | RelationshipDirector |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| Paragon Health Capital, LLC | CRD300729 | Broker-dealer— | Offerings4 |
Facts
As its latest Form D states them
- Industry
- Pharmaceuticals
- State
- Illinois (IL)
- Exemptions
- Rule 506(b)
- First filed
- 2018-08-14
- Latest filing
- 2025-07-08
- Minimum investment
- $1.1K
Who backs Paragon Biosciences Emalex Capital, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗